Xarelto Back On Track: J&J Answers "Complete Response" Letter And Files For Atrial Fibrillation
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Johnson & Johnson and Bayer HealthCare may gain a market advantage if regulators grant an approval with indications for both chronic and acute use of its anticoagulant rivaroxaban, based on regulatory filings the co-development partners announced Jan. 5.
You may also be interested in...
Apixaban Study Halted – But It May Not Cause Much Damage To The Program
The Phase III APPRAISE-2 trial of Bristol-Myers Squibb/Pfizer’s apixaban in acute coronary syndrome has been terminated due to increased bleeding, on the recommendation of a data safety monitoring committee.
Bristol/Pfizer's Apixaban Gets A Chance At The Inside Track
FDA has agreed to review the anticoagulant based on the results of the AVERROES trial, offering a potentially faster route to market.
FDA Plays It Safe With Boehringer Ingelheim's Pradaxa By Approving A Single Dosing Option
Regulators accept bleeding risk for superiority over warfarin, staying away from a temptingly safer but less effective dabigatran dose.